Regeneron Pharmaceuticals Inc. buy Canaccord Genuity Group Inc.
Start price
21.08.23
/
50%
€762.50
Target price
21.08.24
€910.85
Performance (%)
39.08%
End price
22.08.24
€1,060.5
Summary
This prediction ended on 22.08.24 with a price of €1,060.5. The BUY prediction by Canaccord_Genuity_Gr for Regeneron Pharmaceuticals Inc. saw massive gains of 39.08%. Canaccord_Genuity_Gr has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -3.619% | -3.619% | 4.004% |
| iShares Core DAX® | -3,51 % | -8,75 % | -1,00 % |
| iShares Nasdaq 100 | -2,78 % | -0,63 % | 14,22 % |
| iShares Nikkei 225® | -2,04 % | -6,84 % | 24,87 % |
| iShares S&P 500 | -2,60 % | -2,23 % | 9,20 % |
Comments by Canaccord_Genuity_Gr for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Canaccord Genuity Group Inc. from a "hold" rating to a "buy" rating. They now have a $992.00 price target on the stock, up previously from $720.00.
Ratings data for REGN provided by MarketBeat
In the thread Trading Regeneron Pharmaceuticals Inc.
Die von Canaccord_Genuity_Gr gewählte maximale Laufzeit wurde überschritten